You are hereBlogs / Ian Dettman's blog / Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer
Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer
Abstract
AIM:
The aim of this study was to test for the influence of ascorbic acid on tumorigenicity and metastases of implanted PAIII prostate cancer adenocarcinoma cells in syngeneic LW rats.
MATERIALS AND METHODS:
Hormone-refractory prostate cancer PAIII cells were implanted subcutaneously into immunologically intact, Lobund-Wistar (LW) rats. Intraperitoneal pharmacological doses of ascorbic acid were administered each day for the ensuing 30 days. On the 40th day, animals were sacrificed. Local tumor weights were measured, and metastases were counted.
RESULTS:
At the end of the 40 day experimental period, the primary tumors were found to be significantly reduced in weight (p=0.026). In addition, sub-pleural lung metastases were even more profoundly reduced in number and size (p=0.009). Grossly enlarged ipsilateral lymph node metastases declined from 7 of 15 rats to 1 of 15 rats.
CONCLUSION:
Pharmacological doses of ascorbic acid suppress tumor growth and metastases in hormone-refractory prostate cancer.
Pollard HB, Levine MA, Eidelman O, Pollard M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo. 2010 May-Jun;24(3):249-55. PubMed PMID: 20554995
Access to Parenteral Thiamine
Biological Therapies supplies a range of registered injections containing parenteral thiamine.
See the TGA website: http://www.tga.gov.au/safety/alerts-medicine-ivthiamine-100728.htm
See also the SHPA website: SHPA Manufacturers Alerts (Thiamine Injection)
